Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately

The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet